ARCHIVES

Rauscher Explains Reasons for Treatment Switches

This article is from The Cancer Letter archive.

Vol. 01 No. 19 | May 9, 1975

Download PDF Visit The Full Archive

Related Articles

Book For Survivors, Other New Publications

August 23, 1991

Perjeta, Herceptin & Docetaxel Combination Extended Survival in HER2-Positive Disease

December 28, 2012

NIH Selects 16 Clinical Centers for Women’s Health Initiative

April 9, 1993

FASEB: Focus on Research Funding, Not PR

June 14, 2013

Cancer Letter Closes Out 1983, 10th Year

December 16, 1983

BMS Execs Knew Of Flaws In ImClone Plan For C225 Prior To $2-Billion Licensing Deal

June 21, 2002